Physician profile
Mauricio Levine
NPI 1407833031
$1,246.35
in general payments reported to CMS, 2019-2025
17 companies · $436 in 2025
The $436 reported for 2025 was more than what 76% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $388 · 2020: $99.74 · 2021: $103 · 2022: $70.22 · 2023: $62.80 · 2024: $86.73 · 2025: $436.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $585.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $585.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mayne Pharma Commercial LLC | $303.57 | 2023-2025 | |
| Roche Diagnostics Corporation | $140.82 | 2019-2021 | |
| Coopersurgical, INC. | $134.29 | 2024-2025 | Paragard T 380a |
| Merck Sharp & Dohme LLC | $130.09 | 2019-2020 | |
| Abbvie INC. | $99.77 | 2019-2022 | |
| Therapeuticsmd, INC. | $69.68 | 2019-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $59.74 | 2019-2020 | |
| Astellas Pharma US INC | $57.48 | 2024 | Veozah |
| Hologic Sales and Service, LLC | $46.40 | 2019-2025 | Aptima |
| Allergan, INC. | $46.40 | 2019 | |
| Shield Therapeutics INC | $36.42 | 2025 | |
| Myovant Sciences INC. | $27.11 | 2021 | |
| Daiichi Sankyo INC. | $25.20 | 2023 | Injectafer |
| Organon LLC | $24.20 | 2022 | |
| Convatec INC. | $16.51 | 2019 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Minerva Surgical, INC | $15.61 | 2019 | |
| Dysis Medical, INC. | $13.06 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mauricio Levine listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.